Opendata, web and dolomites

VacPath SIGNED

Novel vaccine vectors to resist pathogen challenge

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VacPath project word cloud

Explore the words cloud of the VacPath project. It provides you a very rough idea of what is the project "VacPath" about.

exploited    combated    infectious    trachomatis    constant    induction    intracellular    virus    combination    populations    mechanisms    unravel    urging    burden    re    academic    academia    insufficient    uncover    optimisation    underlying    vector    protective    ready    stage    chlamydia    preclinical    vaccinate    vaccines    innovative    antibiotics    diverse    demand    infection    esr    world    bacterial    training    barely    cell    safe    creative    induce    sexually    threat    immunity    economies    industry    cooperate    force    infections    molecular    construct    danger    cellular    perceived    nevertheless    models    plasmid    scientists    frequently    mediated    pathogen    disease    spread    vaccine    too    obligate    poses    prophylactic    educate    bacterium    possibilities    pathogens    raised    humoral    imposed    back    persistence    diseases    resistance    ago    enter    health    humans    solutions    vectors    responsive    globe    hampers    generation    efficacy    immune    transmitted    private    rapid   

Project "VacPath" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙701˙874 €
 EC max contribution 2˙701˙874 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 531˙239.00
2    UNIVERSITAT BASEL CH (BASEL) participant 562˙553.00
3    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 505˙576.00
4    STATENS SERUM INSTITUT DK (KOBENHAVN S) participant 297˙522.00
5    ABERA BIOSCIENCE AB SE (STOCKHOLM) participant 281˙982.00
6    MICROBIOTEC SRL IT (MONTERIGGIONI) participant 261˙499.00
7    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 261˙499.00
8    SCLAVO VACCINES ASSOCIATION IT (SIENA) partner 0.00

Map

 Project objective

Infectious diseases are a major burden and constant threat to European populations and economies. While barely perceived as a danger not too long ago, a combination of potential rapid spread of novel pathogens across the globe, antibiotics resistance, a come-back of “old” pathogens and persistence of yet to be combated pathogens has raised the demand for effective but safe vaccines. An example of a yet to be combated pathogen is the obligate intracellular bacterium Chlamydia trachomatis. This pathogen is the major cause of sexually transmitted bacterial disease in humans, and poses a world-wide health concern. While responsive to antibiotics, re-infections frequently occur, urging the need for a prophylactic vaccine. Nevertheless, insufficient knowledge on how to vaccinate against intracellular pathogens hampers the development of such vaccines. In the proposed project, 5 academic and 2 private partners will cooperate to educate early stage researchers (ESR) in the diverse aspects of novel vaccine development. ESR will design and construct innovative and safe virus-, bacterium-, and plasmid-based vaccine vectors that induce both cell-mediated and humoral immunity, to control infections with intracellular pathogens. They will test these vaccines and improve their efficacy in preclinical models of C. trachomatis infection, and unravel the cellular and molecular mechanisms underlying the induction of protective immune responses, to uncover possibilities for general vaccine vector optimisation. The end-result will be a new generation of safe vaccine vectors that can be exploited to vaccinate against C. trachomatis, and can be adapted to vaccinate against further intracellular pathogens of choice. Moreover, this project will educate a new generation of scientists that, through the offered, integrated training, will be ready to enter the European task force, in academia or industry, to find creative solutions to future pathogen-imposed challenges.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACPATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACPATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

DESIGN-EID (2020)

Defect Simulation and Material Growth of III-V Nanostructures- European Industrial Doctorate Program

Read More  

LIVE-I (2020)

Lightening and Innovating transmission for improving Vehicle: Environmental Impacts

Read More